Celgene Corporation / Avila Therapeutics, Inc.

B-cell Hematologic Malignancies (CLL/NHL)

21K US cases/yr

Disease Overview

Chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphomas are blood cancers driven by abnormal proliferation of mature B-lymphocytes. They affect mostly older adults (median age ~70), are largely incurable in advanced/relapsed settings, and rely on B-cell receptor signaling — making BTK a validated therapeutic target.

Competitive Landscape

At the time of the Avila deal (Jan 2012), the BTK inhibitor space was crystallizing around Pharmacyclics/J&J's PCI-32765 (later ibrutinib/Imbruvica), then in Phase 2 with breakthrough single-agent activity in CLL and MCL. Standard of care was still chemoimmunotherapy regimens (FCR — fludarabine/cyclophosphamide/Rituxan and BR — bendamustine/Rituxan). Avila's AVL-292 (later CC-292) was a more selective covalent BTK inhibitor positioned as a potentially cleaner second-generation alternative to ibrutinib, with the Avilomics covalent platform offering pipeline optionality beyond hematology into autoimmune disease (LifeSciVC, Jan 26 2012). For Celgene — whose hematology franchise rested on Revlimid, Vidaza, and Thalomid — adding a covalent BTK program complemented its myeloma/MDS dominance and gave it a CLL/NHL entry against Roche's rituximab/obinutuzumab and the emerging ibrutinib wave. CC-292 was ultimately deprioritized after ibrutinib's 2013 approval set a high efficacy bar; the broader Avilomics platform value (including future BTK-targeted autoimmune assets) remained the longer-term thesis. Source: https://lifescivc.com/2012/01/avila-therapeutics-strikes-a-covalent-corporate-bond-with-celgene/